Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Benhamou

Showing results (121-130 of 168) with videos related to

Pageof 17
Sort By:
Diabetes Technology & Therapeutics|October 28, 2014
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetesF Javier Ampudia-Blasco, Pierre Yves Benhamou, Guillaume Charpentier, et al.
Diabetes, Obesity & Metabolism|October 18, 2019
Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exerciseHélène Hanaire, Sylvia Franc, Sophie Borot, et al.
Hepatology (Baltimore, Md.)|July 31, 2008
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CStefan Zeuzem, Eric M Yoshida, Yves Benhamou, et al.
Transplantation|February 24, 2011
Influence of donor age on islet isolation and transplantation outcomeNadja Niclauss, Domenico Bosco, Philippe Morel, et al.
BMJ Open Diabetes Research & Care|February 25, 2025
Clinical phenotyping of people living with type 1 diabetes according to their levels of diabetes-related distress: results from the SFDT1 cohortDulce Canha, Gloria Aguayo, Emmanuel Cosson, et al.
Gastroenterologie Clinique Et Biologique|March 28, 2006
Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-upCécile Poupardin, Marc Lémann, Jean-Pierre Gendre, et al.
Journal of Hepatology|May 29, 2013
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis CThierry Poynard, Joseph Moussalli, Mona Munteanu, et al.
Transplantation|April 29, 2004
Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL networkLaurence Kessler, Pascal Bucher, Laure Milliat-Guittard, et al.
Plos One|July 4, 2008
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadYen Ngo, Yves Benhamou, Vincent Thibault, et al.
Diabetes Care|June 13, 2015
Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL NetworkSandrine Lablanche, Sophie Borot, Anne Wojtusciszyn, et al.
Pageof 17

Showing results (121-130 of 168) with videos related to

Sort By:
Pageof 17
Diabetes Technology & Therapeutics|October 28, 2014
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetesF Javier Ampudia-Blasco, Pierre Yves Benhamou, Guillaume Charpentier, et al.
Diabetes, Obesity & Metabolism|October 18, 2019
Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exerciseHélène Hanaire, Sylvia Franc, Sophie Borot, et al.
Hepatology (Baltimore, Md.)|July 31, 2008
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CStefan Zeuzem, Eric M Yoshida, Yves Benhamou, et al.
Transplantation|February 24, 2011
Influence of donor age on islet isolation and transplantation outcomeNadja Niclauss, Domenico Bosco, Philippe Morel, et al.
BMJ Open Diabetes Research & Care|February 25, 2025
Clinical phenotyping of people living with type 1 diabetes according to their levels of diabetes-related distress: results from the SFDT1 cohortDulce Canha, Gloria Aguayo, Emmanuel Cosson, et al.
Gastroenterologie Clinique Et Biologique|March 28, 2006
Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-upCécile Poupardin, Marc Lémann, Jean-Pierre Gendre, et al.
Journal of Hepatology|May 29, 2013
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis CThierry Poynard, Joseph Moussalli, Mona Munteanu, et al.
Transplantation|April 29, 2004
Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL networkLaurence Kessler, Pascal Bucher, Laure Milliat-Guittard, et al.
Plos One|July 4, 2008
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadYen Ngo, Yves Benhamou, Vincent Thibault, et al.
Diabetes Care|June 13, 2015
Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL NetworkSandrine Lablanche, Sophie Borot, Anne Wojtusciszyn, et al.
Pageof 17